BMA 120 is an endothelial cell specific monoclonal antibody that can be used to label angiosarcoma cells in routinely prepared tissues.
Answers are grounded in this paper and cite their sources.
BMA 120 may label angiosarcoma cells in routine tissues; leaves open comparative utility versus established endothelial markers.
Since the advent of endothelial cell specific antibodies, immunocytochemistry has become an increasingly used tool in the diagnosis of malignant endothelial tumors or tumors of an alleged vascular nature. In surgical pathology the most frequently applied markers are anti-Factor VIII-related antigen (anti-FVIII-R:AG) and Ulex europeus I agglutinin (UEA I) because of their ability to work on routinely formalin-fixed paraffin-embedded tissue. However, these markers label angiosarcomas inconstantly, which has prompted the search for more reliable markers, especially monoclonal antibodies specific for endothelial cell specific antigens. BMA 120 (formerly designated BW 200) is an endothelial cell specific monoclonal antibody detecting an epitope of a formalin resistant antigen. This marker labels a considerable number of angiosarcoma cells and it was compared with the staining patterns of anti-FVIIIR:Ag and UEA I in 19 angiosarcomas. Special regard was given to the distribution of antibodies in different parts of angiosarcomas.
No takes yet. Share an insight, caveat, or question.
Alles et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: